Summit and Sarepta to collaborate on muscular dystrophy drug

(Reuters) - Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.